Clinical Trials

Multiple novel combos of PD-(L)1 x VEGF-targeting bispecific antibodies and antibody-drug conjugates progressed through the clinic this year, many of which are from Chinese developers and with some advancing to first-line regimens.

The drugmaker announced positive topline results from its two Phase III trials of zasocitinib, a TYK2 inhibitor, in plaque psoriasis.

Positive topline data from the EV-304/KEYNOTE-B15 Phase III trial in cisplatin-eligible muscle invasive bladder cancer follows hot on the heels of the combination's stellar results in chemotherapy-ineligible patients.

After a developmental rollercoaster ride, the French firm is getting ready to refile Viaskin Peanut for 4-7 -year-olds in the first half of 2026.

The California firm announced positive data from its early-stage randomized study of TLC-6740 combined with Lilly’s tirzepatide in patients with obesity.

Clinical Data Readout: As a worldwide first mover, InnoCare’s BTK inhibitor orelabrutinib has hit its monotherapy primary endpoint of SRI-4 response rate at 48 weeks in a China-only Phase IIb trial in systemic lupus erythematosus.

The companies presented 52-week data from the pivotal Phase III VERIFY study at the recent American Society of Hematology meeting, after releasing 32-week data earlier this year.

With two late-stage lupus assets finishing recruitment and a newly acquired nephrology franchise running three concurrent Phase III programs, Biogen is making its most significant commitment yet to immunology beyond its legacy MS business.

Lupeng's BTK inhibitor rocbrutinib has shown an 80.0% ORR in a Phase I trial in patients who had received a covalent or non-covalent BTK inhibitor plus BCL-2 inhibitor, setting the stage for a comparative trial, possibly with Jaypirca.

Senior Indegene executive discusses why pharma R&D organizations of the future will need to be agile, modular and AI-native by design. Industry pilots are pointing the way to potential one click regulatory submissions.

To develop bispecific, dual-payload antibody-drug conjugates, Phrontline Biopharma’s strategy is to tune the activity of each payload to a similar level and engineer both toxins to fit within a branched linker, its CEO tells Scrip in an interview.

The Polish biotech says that data presented at the Orlando meeting also strengthens its confidence in the CDK8/19 inhibitor's potential across hematologic cancers with limited treatment options.